Antengene Corporation Limited Stock price

Equities

6996

KYG039571008

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
1 HKD -0.99% Intraday chart for Antengene Corporation Limited -10.71% -50.00%

Financials

Sales 2023 67.3M 9.32M 72.97M Sales 2024 * 140M 19.35M 151M Capitalization 623M 86.34M 676M
Net income 2023 -581M -80.49M -630M Net income 2024 * -475M -65.81M -515M EV / Sales 2023 18.2 x
Net Debt 2023 * 57.96M 8.03M 62.83M Net Debt 2024 * 201M 27.85M 218M EV / Sales 2024 * 5.9 x
P/E ratio 2023
-1.93 x
P/E ratio 2024 *
-1.26 x
Employees 201
Yield 2023 *
-
Yield 2024 *
-
Free-Float 53.36%
More Fundamentals * Assessed data
Dynamic Chart
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study CI
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List MT
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance CI
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States CI
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma CI
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day CI
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 CI
Antengene Unaware of Reasons Behind Recent Share Price Drop, Surge in Trade Volume MT
Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hansoh, Antengene Join Forces for Anti-Tumor Tablet Commercialization in China; Antengene Shares Rise 4% MT
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China CI
Hong Kong Regulator Gives Go Ahead to Antengene’s Application for Multiple Myeloma Drug MT
Antengene Says Hong Kong Approves Myeloma Drug MT
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma CI
More news
1 day-0.99%
1 week-10.71%
Current month-19.35%
1 month-20.00%
3 months-46.81%
6 months-18.70%
Current year-50.00%
More quotes
1 week
0.98
Extreme 0.98
1.06
1 month
0.98
Extreme 0.98
1.29
Current year
0.98
Extreme 0.98
2.00
1 year
0.98
Extreme 0.98
3.45
3 years
0.98
Extreme 0.98
20.30
5 years
0.98
Extreme 0.98
22.50
10 years
0.98
Extreme 0.98
22.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 18-08-27
Director of Finance/CFO 42 -
Chief Tech/Sci/R&D Officer - 22-12-15
Members of the board TitleAgeSince
Director/Board Member 57 23-04-13
Chief Executive Officer 58 18-08-27
Chief Operating Officer 40 18-11-01
More insiders
Date Price Change Volume
24-03-28 1 -0.99% 362,500
24-03-27 1.01 0.00% 97,500
24-03-26 1.01 -0.98% 115,000
24-03-25 1.02 -5.56% 578,500
24-03-22 1.08 -3.57% 145,500

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Antengene Corporation Limited is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.9234 CNY
Average target price
1.666 CNY
Spread / Average Target
+80.47%
Consensus
  1. Stock
  2. Equities
  3. Stock Antengene Corporation Limited - Hong Kong S.E.